1. Home
  2. ELVN vs EIG Comparison

ELVN vs EIG Comparison

Compare ELVN & EIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • EIG
  • Stock Information
  • Founded
  • ELVN 2016
  • EIG 2000
  • Country
  • ELVN United States
  • EIG United States
  • Employees
  • ELVN N/A
  • EIG N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • EIG Property-Casualty Insurers
  • Sector
  • ELVN Health Care
  • EIG Finance
  • Exchange
  • ELVN Nasdaq
  • EIG Nasdaq
  • Market Cap
  • ELVN 1.1B
  • EIG 1.3B
  • IPO Year
  • ELVN 2020
  • EIG 2007
  • Fundamental
  • Price
  • ELVN $23.06
  • EIG $51.30
  • Analyst Decision
  • ELVN Strong Buy
  • EIG Strong Buy
  • Analyst Count
  • ELVN 5
  • EIG 1
  • Target Price
  • ELVN $37.80
  • EIG $58.00
  • AVG Volume (30 Days)
  • ELVN 191.8K
  • EIG 141.1K
  • Earning Date
  • ELVN 11-13-2024
  • EIG 02-13-2025
  • Dividend Yield
  • ELVN N/A
  • EIG 2.34%
  • EPS Growth
  • ELVN N/A
  • EIG 20.58
  • EPS
  • ELVN N/A
  • EIG 5.34
  • Revenue
  • ELVN N/A
  • EIG $889,800,000.00
  • Revenue This Year
  • ELVN N/A
  • EIG N/A
  • Revenue Next Year
  • ELVN N/A
  • EIG $1.18
  • P/E Ratio
  • ELVN N/A
  • EIG $9.59
  • Revenue Growth
  • ELVN N/A
  • EIG 5.05
  • 52 Week Low
  • ELVN $10.90
  • EIG $38.38
  • 52 Week High
  • ELVN $30.03
  • EIG $54.44
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 44.52
  • EIG 47.25
  • Support Level
  • ELVN $21.55
  • EIG $50.34
  • Resistance Level
  • ELVN $24.32
  • EIG $51.24
  • Average True Range (ATR)
  • ELVN 1.43
  • EIG 0.77
  • MACD
  • ELVN 0.05
  • EIG -0.10
  • Stochastic Oscillator
  • ELVN 47.24
  • EIG 41.55

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

About EIG Employers Holdings Inc

Employers Holdings Inc provides workers' compensation insurance, to small businesses in low- to medium-hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through itswholly owned subsidiaries.

Share on Social Networks: